idea-016 · vet · active
For single-use, in-clinic instillation and aspiration of sterile isotonic; irrigation fluid in the external ear canal of dogs undergoing ear cleaning or ear flushing; as part of the management of otitis externa, performed by or under the direction of a; licensed veterinarian in a sedated or anaesthetised patient following otoscopic examination; not for the delivery of medicated or therapeutic solutions, not for use in the middle ear; beyond fluid recovered through an already-accessible tympanic defect, and not for home or; owner use.
| Mechanism | A hand-held, single-use, coaxial dual-lumen catheter for the canine external ear; canal. The outer body carries graduated depth markings and an adjustable depth-limiting; collar so the operator sets and holds a known insertion depth. The inner irrigation lumen is; fed from a standard syringe or IV fluid line through an inline mechanical pressure-relief; valve that vents above a fixed cracking pressure, capping delivered irrigation pressure; regardless of how hard the operator pushes the plunger. The outer aspiration lumen connects; to ordinary clinic suction through a volume-graduated inline trap, so the volume instilled; and the volume recovered can be read off and compared as a procedural endpoint ("the canal; and any accessible bulla fluid are cleared") rather than judged by feel. Soft, tapered,; atraumatic tip; a size-matched tip family across canal diameters. No energy source, no; software, no active electronics. |
|---|---|
| Device class | n/a — veterinary-only device. FDA does not premarket-review animal-only devices.; 21 CFR 807.65(b) exempts "a manufacturer of devices to be used solely for veterinary; purposes" from device establishment registration, and 807.20(a) / 807.81(a) / 814.1(a); all attach their duties to devices "intended for human use." This is the launch route,; and it is an absence of a pathway rather than a pathway. See claims 1-2.; NOT LIVE — human-use counterfactual. A human-labelled ear-irrigation / cerumen-management; device would need a US premarket route. The Generator believes such devices sit somewhere; within 21 CFR part 874 (ear, nose, and throat devices) but did not identify the; section, did not identify a product code, and ran no classification lookup. Recorded as; unexamined rather than guessed. See claim 4. Scoring Factor 1 from this row would score a; different, human-labelled product.; NOT LIVE — animal-drug boundary, carried because it is the thing indication scope is; protecting against. If the same hardware were labelled to instill a medicated or; therapeutic solution with a claim to treat infection, the product would engage FDA CVM's; animal-drug apparatus (new animal drug approval, 21 U.S.C. 360b / 21 CFR part 514) rather; than the device-side no-premarket position above — a materially heavier route. The; intended use below is scoped to sterile isotonic irrigation fluid specifically to stay off; it. See claim 3. |
| Predicate or analog | No veterinary or human predicate exists in a regulatory sense — FDA does; not premarket-review animal-only devices, so neither this candidate nor any veterinary; analog can hold one. The closest functional analogs identified, all as mechanism and market; analogs only, never as a regulatory predicate: (1) the OtoPet-USA "Earigator," a veterinary; ear irrigation-and-suction console (capital equipment, temperature- and; pressure-controlled) — the incumbent this candidate is deliberately positioned beneath on; price and capital; (2) the human "Earigator" cerumen-management system marketed by Nupur; Technologies; (3) the ad-hoc standard of care, a 5-8 Fr red rubber urinary catheter on a; syringe with separate suction — the technique this candidate is actually competing to; replace; (4) pressure-controlled pulsed lavage in human wound care (e.g. Stryker InterPulse); as the closest analog for the pressure-limiting element specifically. No single-use,; pressure-limited, dual-lumen veterinary ear-irrigation catheter was identified. That absence; is a web-search result, not an established fact — see claim 20. |
| Launch jurisdiction | US |
| Target | vet |
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The coverage above says how much is known. This says what any of it is for: the propositions this opportunity rests on, ordered by what a failure would cost and, inside that, by what settling it would take. Derived from the pillars and the claims' current tags, not written.
This packet is unassessed. Its claims carry tags, so the file says how sure anybody is about each one — and nothing says which of them the idea actually rests on, or what it would cost to be wrong about one. Run /assess idea-016 to add that. Unassessed is a state, not a failing score.
This candidate has no ## Wrap section yet, so there is no plain-language summary, no quoted load-bearing condition per lens, and no named cheapest next test. Run /wrap idea-016 to write one.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | Claims 1-2: if they hold, an animal-only intended use has no US premarket submission of any kind — 807.65(b) exempts veterinary-only manufacturers and 807.20(a)/807.81(a)/814.1(a) attach only to human-use devices. Not 5: claim 3's…the rest of this reasoninganimal-drug boundary is the live risk in this lane and is itself unverified, and the frontmatter's part-874 row is NOT LIVE and was not scored. | Full-text eCFR read of 807.65(b), 807.20(a), 807.81(a), 814.1(a) against this intended-use statement, plus 21 CFR part 514 and 21 U.S.C. 360b for the claim-3 boundary — free, about an hour. |
| Reimbursement pathway | 1 | Claims 14, 15: no CPT, no HCPCS, no LCD/NCD and no third-party payer exists for a veterinary procedure; the practice buys the consumable and the owner pays out of pocket, with pet insurance at a low single-digit share of US pets. Scored as…the rest of this reasoninga floor, not as "pending research" — there is no code to find. Not 0: a functioning cash-pay channel through practice purchasing is asserted. | Negative CPT/HCPCS/coverage lookups confirm the absence at no cost. The evidence that would actually move this is the primary NAPHIA State of the Industry report and a veterinary practice-management price list showing what an ear-flush…the rest of this gap analysisline item bears — one free, one licensed. |
| TAM | 2 | Claims 5, 6, 7 give a population leg (Banfield-reported 15.8% otitis externa, corroborated by a 5-20% practice range) and claim 10 an 80-90M US dog base; claims 11 (20-40% flushed in-clinic) and 12 ($12-25/kit) are stated by the Generator…the rest of this reasoningas assumptions with no source. If all four held, the implied US procedure revenue clears the 2/5 floor but not comfortably. Claim 13 flags every one of these as connector-unreachable. | The primary Banfield State of Pet Health report for the population leg (free, one document), plus a licensed veterinary practice-management dataset (e.g. VetSuccess/Vetsource) for flush-procedure share and consumable pricing — licensed,…the rest of this gap analysisreal cost, human-attached. |
| FTO / IP | 1 | Claims 18-19: no patent search of any kind was performed and no number, family, assignee or expiry is named; claim 19 is explicitly an assumption and does not raise this score. Claim 17 removes the lane's usual advantage here — 35 U.S.C.…the rest of this reasoning271(a) reaches making/using/selling without reference to species, so the veterinary exemption buys nothing on this factor. Not 0: nothing is known to block, either. | A USPTO/Google Patents search against the named targets — OtoPet-USA, Nupur Technologies, Stryker InterPulse, and ENT irrigation-suction handpieces — a few hours of analyst time, free. A clearance opinion needs outside counsel and real…the rest of this gap analysismoney. |
| Moat / defensibility | 1 | Claim 21: no technical barrier identified that would stop an existing veterinary-consumables manufacturer from copying the device once shipped; all three proposed levers (bench dataset, tip family, distribution) are unquantified and…the rest of this reasoningunestablished. | The bench dataset in claim 21(a) is the only lever that could become defensible, and it does not exist yet. Short of that, a trademark/design-registration and distributor-channel scan of veterinary consumables suppliers — free desk…the rest of this gap analysisresearch, a few hours. |
| Mechanism & clinical risk | 2 | Claim 8 says the failure modes the device targets (tympanic rupture, ototoxicity, vestibular signs) are real and documented, and the hardware is passive — no energy, no software. Held down by claim 9, a named hole: no published canine…the rest of this reasoningtympanic rupture pressure threshold was found, so the relief valve's cracking pressure has no numerical basis; and by claim 24, the instilled-vs-recovered endpoint is an untested hypothesis. | A cadaveric canine temporal-bone study establishing the irrigation-pressure rupture threshold (claim 9) — a funded bench programme, weeks and real money. Claim 8's failure modes are settleable free via PubMed. |
| Capital intensity & time-to-revenue | 3 | Inferred from claims 1-2 (no premarket submission to fund or wait on) and the mechanism's simplicity as a moulded single-use disposable. Held to 3 because claims 9 and 24 put a bench programme ahead of launch, and no claim in this file…the rest of this reasoninggives an actual build cost or time-to-first-dollar. | Contract-manufacturer quotes for a moulded dual-lumen disposable plus a costed bench-programme plan — a human-attached estimate, no fixed price. |
| Competitive intensity | 3 | Claim 20 names OtoPet-USA's veterinary Earigator console and Nupur's human system and found no single-use pressure-limited dual-lumen catheter — but claim 20 itself says that absence is only a missed web-search hit and must not be scored…the rest of this reasoningas white space. Claim 16's entrenched red rubber catheter and syringe is the real competitor, and it is nearly free. | OtoPet-USA and veterinary distributor catalogue pricing for the console (free). A primary practice survey of current ear-flush technique would settle claim 16's share question — real money and weeks. |
| Strategic fit & portfolio balance | — | none — no numbered claim in this file addresses fit against the current portfolio. The prose note that idea-002, idea-007 and idea-012 share the veterinary regulatory lever is not written as a claim and was not scored. | Not connector-checkable — a Tier 3 human portfolio judgement, free but requiring a human decision. |
To finish this packet:
domains: — run /research## Wrap section with a **Cheapest next test:** lineDomain dossier: none linked
Source file: knowledge-base/candidates/idea-016.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.